The present invention relates to compounds of Formula (I) and/or Formula (Ia):
and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.
The present invention relates to compounds of Formula (I) and/or Formula (Ia):
and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.
[EN] SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF<br/>[FR] SULFONAMIDES AYANT DES ACTIVITÉS D'INHIBITION DE L'EGFR ET LEUR UTILISATION
申请人:ACCUTAR BIOTECHNOLOGY INC
公开号:WO2022170164A1
公开(公告)日:2022-08-11
The invention provides compounds and pharmaceutical compositions thereof, which are useful for inhibiting one or more mutations of EGFR, as well as methods for using such compounds to treat cancer associated with EGFR mutations.
[EN] N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE N2-PHÉNYLPYRIMIDINE-2,4-DIAMINE ET PROCÉDÉS DE PRÉPARATION ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
申请人:BRIDGE BIOTHERAPEUTICS INC
公开号:WO2022208454A1
公开(公告)日:2022-10-06
The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as an active ingredient. The novel N2- phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.